Tag Archives: 2011 GI Symposium

Chemo Delay After Surgery Reduces Survival Rates

A paper presented at the recent 2011 Gastrointestinal Cancers Symposium conference reported important evidence that, for colorectal cancer patients getting chemotherapy after surgery, the sooner the better. For people diagnosed with stage III colon cancer, stage II rectal cancer, or stage II colon cancer showing certain high-risk features, researchers found that each four-week delay in starting chemotherapy after surgery was associated with a 12% lower rate of survival five years later.

Leading GI Cancer Researcher Updates Patients

Last night, Dr. Edith Mitchell of Thomas Jefferson University Kimmel Cancer Center in Philadelphia, PA, updated colorectal cancer patients on the latest research and treatment news in an online webinar. Dr. Mitchell highlighted the most important news for colon and rectal cancer patients to come from the 2011 Gastrointestinal Cancers Symposium held in San Francisco last month. She answer such questions as… “Can doctors determine the chances that my cancer may return?” “Can my doctors determine if I need chemotherapy?” “Does Avastin or Erbitux benefit my stage III cancer treatment?” “Are there any promising new treatments on the horizon?”

Specialized Radiation "Paints" a Safer Picture for Anal Cancer

Serious side effects were reduced when research radiologists used a special technique to target the most radiation on anal cancer tumors, while sparing nearby normal tissue. Reported at the recent 2011 Gastrointestinal Cancers Symposium in San Francisco, intensity-modulated radiation therapy (IMRT) did not reduce overall side effects during chemotherapy and radiation treatment, but it did cut down on the most serious bladder, bowel, and skin problems. At the same time, IMRT was a good as traditional external beam radiation in preventing local recurrences and the need for colostomies.  Survival after two years was also similar to a previous study that did not use the technique.

Specialized Radiation “Paints” a Safer Picture for Anal Cancer

Serious side effects were reduced when research radiologists used a special technique to target the most radiation on anal cancer tumors, while sparing nearby normal tissue. Reported at the recent 2011 Gastrointestinal Cancers Symposium in San Francisco, intensity-modulated radiation therapy (IMRT) did not reduce overall side effects during chemotherapy and radiation treatment, but it did cut down on the most serious bladder, bowel, and skin problems. At the same time, IMRT was a good as traditional external beam radiation in preventing local recurrences and the need for colostomies.  Survival after two years was also similar to a previous study that did not use the technique.

Top